NovoCure Limited (NVCR)
USD 31.54
(-1.73%)
USD 31.54
(-1.73%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.14 Billion USD | -3.82% |
| 2022 | 1.19 Billion USD | 4.58% |
| 2021 | 1.13 Billion USD | 8.32% |
| 2020 | 1.05 Billion USD | 119.42% |
| 2019 | 479.44 Million USD | 41.1% |
| 2018 | 339.79 Million USD | 28.08% |
| 2017 | 265.29 Million USD | -5.95% |
| 2016 | 282.08 Million USD | -8.22% |
| 2015 | 307.33 Million USD | 160.73% |
| 2014 | 117.87 Million USD | -37.6% |
| 2013 | 188.91 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.12 Billion USD | -2.16% |
| 2024 Q2 | 1.21 Billion USD | 8.09% |
| 2024 Q3 | 1.22 Billion USD | 0.81% |
| 2023 Q4 | 1.14 Billion USD | -0.02% |
| 2023 Q3 | 1.14 Billion USD | -1.09% |
| 2023 Q2 | 1.15 Billion USD | -1.3% |
| 2023 Q1 | 1.17 Billion USD | -1.45% |
| 2023 FY | 1.14 Billion USD | -3.82% |
| 2022 Q2 | 1.16 Billion USD | 1.08% |
| 2022 FY | 1.19 Billion USD | 4.58% |
| 2022 Q3 | 1.17 Billion USD | 0.99% |
| 2022 Q4 | 1.19 Billion USD | 1.48% |
| 2022 Q1 | 1.15 Billion USD | 0.94% |
| 2021 Q2 | 1.09 Billion USD | 2.76% |
| 2021 FY | 1.13 Billion USD | 8.32% |
| 2021 Q3 | 1.12 Billion USD | 2.13% |
| 2021 Q4 | 1.13 Billion USD | 1.7% |
| 2021 Q1 | 1.06 Billion USD | 1.49% |
| 2020 Q2 | 528.93 Million USD | 5.27% |
| 2020 FY | 1.05 Billion USD | 119.42% |
| 2020 Q4 | 1.05 Billion USD | 144.05% |
| 2020 Q3 | 431.04 Million USD | -18.51% |
| 2020 Q1 | 502.44 Million USD | 4.8% |
| 2019 Q4 | 479.44 Million USD | 8.02% |
| 2019 FY | 479.44 Million USD | 41.1% |
| 2019 Q3 | 443.85 Million USD | 9.27% |
| 2019 Q2 | 406.18 Million USD | 9.71% |
| 2019 Q1 | 370.25 Million USD | 8.96% |
| 2018 Q4 | 339.79 Million USD | 7.7% |
| 2018 FY | 339.79 Million USD | 28.08% |
| 2018 Q1 | 303.47 Million USD | 14.39% |
| 2018 Q2 | 309.87 Million USD | 2.11% |
| 2018 Q3 | 315.51 Million USD | 1.82% |
| 2017 Q4 | 265.29 Million USD | 1.15% |
| 2017 FY | 265.29 Million USD | -5.95% |
| 2017 Q1 | 264.62 Million USD | -6.19% |
| 2017 Q2 | 257.04 Million USD | -2.87% |
| 2017 Q3 | 262.27 Million USD | 2.04% |
| 2016 FY | 282.08 Million USD | -8.22% |
| 2016 Q4 | 282.08 Million USD | -3.1% |
| 2016 Q3 | 291.09 Million USD | 16.2% |
| 2016 Q2 | 250.51 Million USD | -10.21% |
| 2016 Q1 | 279.01 Million USD | -9.21% |
| 2015 Q2 | 192.77 Million USD | 62.21% |
| 2015 FY | 307.33 Million USD | 160.73% |
| 2015 Q1 | 118.83 Million USD | 0.82% |
| 2015 Q4 | 307.33 Million USD | 76.85% |
| 2015 Q3 | 173.78 Million USD | -9.85% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 117.87 Million USD | -37.6% |
| 2014 Q4 | 117.87 Million USD | 0.0% |
| 2013 FY | 188.91 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 180.36 Million USD | -535.436% |
| AngioDynamics, Inc. | 317.67 Million USD | -260.791% |
| AtriCure, Inc. | 613.93 Million USD | -86.687% |
| Avinger, Inc. | 13.77 Million USD | -8223.377% |
| Azenta, Inc. | 2.88 Billion USD | 60.283% |
| BioLife Solutions, Inc. | 412.71 Million USD | -177.705% |
| The Cooper Companies, Inc. | 11.65 Billion USD | 90.169% |
| Daxor Corporation | 34.86 Million USD | -3186.944% |
| Ekso Bionics Holdings, Inc. | 28.91 Million USD | -3863.376% |
| Femasys Inc. | 27.75 Million USD | -4029.328% |
| GlucoTrack, Inc. | 4.9 Million USD | -23266.544% |
| Harvard Bioscience, Inc. | 137.36 Million USD | -734.361% |
| Hologic, Inc. | 9.15 Billion USD | 87.482% |
| ICU Medical, Inc. | 4.37 Billion USD | 73.823% |
| Intuitive Surgical, Inc. | 15.44 Billion USD | 92.578% |
| KORU Medical Systems, Inc. | 28.46 Million USD | -3927.02% |
| LeMaitre Vascular, Inc. | 346.77 Million USD | -230.508% |
| Innovative Eyewear, Inc. | 6.21 Million USD | -18330.18% |
| Innovative Eyewear, Inc. | 6.21 Million USD | -18330.18% |
| Masimo Corporation | 3.04 Billion USD | 62.317% |
| Microbot Medical Inc. | 8.32 Million USD | -13664.009% |
| Meihua International Medical Technologies Co., Ltd. | 171.91 Million USD | -566.682% |
| Merit Medical Systems, Inc. | 2.32 Billion USD | 50.709% |
| Nephros, Inc. | 11.86 Million USD | -9563.005% |
| NEXGEL, Inc. | 9.95 Million USD | -11413.099% |
| NEXGEL, Inc. | 9.95 Million USD | -11413.099% |
| Singular Genomics Systems, Inc. | 265.46 Million USD | -331.741% |
| OraSure Technologies, Inc. | 482.84 Million USD | -137.37% |
| Pro-Dex, Inc. | 54.21 Million USD | -2014.239% |
| Pulse Biosciences, Inc. | 60.8 Million USD | -1784.957% |
| Predictive Oncology Inc. | 14.41 Million USD | -7849.707% |
| Precision Optics Corporation, Inc. | 16.91 Million USD | -6676.786% |
| QuidelOrtho Corporation | 8.56 Billion USD | 86.615% |
| Repligen Corporation | 2.82 Billion USD | 59.421% |
| Sanara MedTech Inc. | 73.87 Million USD | -1451.525% |
| STAAR Surgical Company | 488.69 Million USD | -134.53% |
| Sharps Technology, Inc. | 11.78 Million USD | -9621.8% |
| Utah Medical Products, Inc. | 135.45 Million USD | -746.114% |
| DENTSPLY SIRONA Inc. | 7.37 Billion USD | 84.449% |
| Jin Medical International Ltd. | 32.9 Million USD | -3383.31% |